Measuring the impact of the substitution of innovator biologics with biosimilars on uptake and costs among Ontario public drug benefit recipients
Iacono A, Ho M, Yang J, Campbell T, Wynne W, Shearer D, Andersen L, Majer E, Ledlie S, Tadrous M, Gomes T. Clin Pharmacol Ther. 2026; Jan 27 [Epub ahead of print].